The Need for Classification Criteria of Immune Checkpoint Inhibitor-induced inflammatory Arthritis: A Scoping Review

Area of Science:

• Oncology
• Rheumatology
• Immunology

Background:

• Immune checkpoint inhibitors (ICIs) are crucial cancer therapies.
• Immune-related adverse events (irAEs) can occur with ICI use.
• Immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is a significant irAE.

Purpose of the Study:

• To aggregate and synthesize descriptions of ICI-IA from existing literature.
• To highlight key clinical attributes of ICI-IA.
• To discuss conditions that mimic ICI-IA.

Main Methods:

• Scoping review methodology.
• Systematic literature search for ICI-IA descriptions.
• Categorization of findings into symptoms, signs, imaging, and laboratory data.

Main Results:

• ICI-IA exhibits diverse clinical presentations.
• Key attributes include specific symptoms, physical signs, and characteristic imaging/laboratory findings.
• Differential diagnosis must consider mimic conditions.

Conclusions:

• Standardized definitions and classification for ICI-IA are needed.
• A comprehensive understanding of ICI-IA attributes aids diagnosis and management.
• Further research is warranted to refine diagnostic criteria and treatment strategies.